B+
Bull case
30%
Probability
Target price
$58.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
MRNA
ModernaFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The post-earnings bull read is that Q1 showed real top-line recovery, driven by international COVID sales and new European approvals, while R&D and SG&A both declined year over year and management reiterated 2026 growth and cost-discipline targets [#8-K-2026-05-01].
Posture
Defensive
Lead driver
Value
What changed
3 setup hits (3d) with net bullish as of 2026-09-08.
What can break
A $950 million settlement payment is expected in Q3 2026, creating a real cash outflow after the Q1 non-cash litigation charge [#8-K-2026-05-01].
Momentum
100
Value
41
Sentiment
0
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $43.00 · Bull $58.00 · Bear $30.00Analysis 2026-05-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-08 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-08
Investment thesis
As of 2026-09-08
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-08. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Bullish
Target $109.67
Why
Momentum100 · Δ7d +0.0
Value41 · Δ7d -0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-09-08.
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • A $950 million settlement payment is expected in Q3 2026, creating a real cash outflow after the Q1 non-cash litigation charge [#8-K-2026-05-01].
- • Moderna said it is awaiting further FDA guidance on refiling the flu plus COVID combination vaccine, leaving U.S. timing uncertain [#8-K-2026-05-01].
- • The bear read is that the revenue beat leaned heavily on international partnership deliveries, GAAP loss quality was hurt by the $0.9 billion litigation settlement charge, U.S.
Catalyst clock
2026-05-15
Post-earnings estimate digestion after Q1 revenue beat
Lead driver: Value · See fundamentals
Momentum
100
9% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+36.2
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
0
62% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-26.5
Why this grade
Composite grade F. Momentum 99.8 / Value 41.2 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-04. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$43.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$25.73B
Beta
1.31
Shares Out
399.24M
P/E (TTM) · Derived
-8.9
P/S (TTM)
5.63
P/FCF (TTM) · Derived
-20.46
Rev YoY
+2.1%
EPS YoY
-7.6%
Gross Margin
+12.6%
Op Margin
-149.0%
Net Debt
-$4.5B
Current Ratio
2.29
As of 2026-09-08 • Updated nightlySource: Internal modelMethods & Data